Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Longhi, A; Bielack, SS; Grimer, R; Whelan, J; Windhager, R; Leithner, A; Gronchi, A; Biau, D; Jutte, P; Krieg, AH; Klenke, FM; Grignani, G; Donati, DM; Capanna, R; Casanova, J; Gerrand, C; Bisogno, G; Hecker-Nolting, S; De Lisa, M; D'Ambrosio, L; Willegger, M; Scoccianti, G; Ferrari, S.
Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients.
Eur J Cancer. 2017; 74(1):9-16
Doi: 10.1016/j.ejca.2016.12.016
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Leithner Andreas
- Windhager Reinhard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Prognosis of extraskeletal osteosarcoma (ESOS) is reported to be poorer than that of skeletal osteosarcoma. This multicenter retrospective study aimed to evaluate factors influencing ESOS prognosis. Members of the European Musculoskeletal Oncology Society (EMSOS) submitted institutional data on patients with ESOS. Data from 274 patients treated from 1981 to 2014 were collected from 16 EMSOS centres; 266 patients were eligible. Fifty (18.7%) had metastases at diagnosis. Of 216 patients with localised disease, 211 (98%) underwent surgery (R0 = 70.6%, R1 = 27%). Five-year overall survival (OS) for all 266 patients was 47% (95% CI 40-54%). Five-year OS for metastatic patients was 27% (95% CI 13-41%). In the analysis restricted to the 211 localised patients who achieved complete remission after surgery 5-year OS was 51.4% (95% CI 44-59%) and 5-year disease-free survival (DFS) was 43% (95% CI 35-51%). One hundred twenty-one patients (57.3%) received adjuvant or neoadjuvant chemotherapy and 80 patients (37.9%) received radiotherapy. A favourable trend was seen for osteosarcoma-type chemotherapy versus soft tissue sarcoma-type (doxorubicin ± ifosfamide) regimens. For the 211 patients in complete remission after surgery, patient age, tumour size, margins and chemotherapy were positive prognostic factors for DFS and OS by univariate analysis. At multivariate analysis, patient age (≤40 years versus >40 years) (P = 0.05), tumour size (P = 0.0001) and receipt of chemotherapy (P = 0.006) were statistically significant prognostic factors for survival. Patient age and tumour size are factors influencing ESOS prognosis. Higher survival was observed in patients who received perioperative chemotherapy with a trend in favour of multiagent osteosarcoma-type regimen which included doxorubicin, ifosfamide and cisplatin. Copyright © 2017 Elsevier Ltd. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Aged -
- Aged, 80 and over -
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Chemoradiotherapy - methods
- Chemoradiotherapy - mortality
- Child -
- Disease-Free Survival -
- Europe - epidemiology
- Female -
- Humans -
- Male -
- Middle Aged -
- Neoadjuvant Therapy -
- Neoplasm Metastasis -
- Neoplasm Recurrence, Local - mortality
- Neoplasm Recurrence, Local - pathology
- Neoplasm Recurrence, Local - therapy
- Osteosarcoma - mortality
- Osteosarcoma - pathology
- Osteosarcoma - therapy
- Retrospective Studies -
- Risk Factors -
- Soft Tissue Neoplasms - mortality
- Soft Tissue Neoplasms - pathology
- Soft Tissue Neoplasms - therapy
- Tumor Burden -
- Young Adult -
- Find related publications in this database (Keywords)
- Extraskeletal osteosarcoma
- Localised osteosarcoma
- EMSOS